Compile Data Set for Download or QSAR
Report error Found 108 Enz. Inhib. hit(s) with all data for entry = 11607
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632954(US20230348453, Compound C2 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632956(US20230348453, Compound C4 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632957(US20230348453, Compound C5 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632965(US20230348453, Compound B3 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632953(US20230348453, Compound C1 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632962(US20230348453, Compound C10 | US12172993, Compound...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632963(US20230348453, Compound C11 | US12172993, Compound...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632965(US20230348453, Compound B3 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632958(US20230348453, Compound C6 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632955(US20230348453, Compound C3 | US12172993, Compound ...)
Affinity DataIC50: 1.59nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632960(US20230348453, Compound C8 | US12172993, Compound ...)
Affinity DataIC50: 2.96nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 3.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632979(US20230348453, Compound D7 | US12172993, Compound ...)
Affinity DataIC50: 3.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632962(US20230348453, Compound C10 | US12172993, Compound...)
Affinity DataIC50: 4.30nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632963(US20230348453, Compound C11 | US12172993, Compound...)
Affinity DataIC50: 4.43nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 5.02nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 6nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632961(US20230348453, Compound C9 | US12172993, Compound ...)
Affinity DataIC50: 6.44nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632967(US20230348453, Compound E2 | N-(4-chloro-2-fluorot...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632975(US20230348453, Compound E13 | N-(2-chloro-4- (difl...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632968(US20230348453, Compound E3 | N-(2-chloro-4-(fluoro...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632973(US20230348453, Compound E11 | N-(2-chloro-4-(fluor...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632971(US20230348453, Compound E9 | N-(2-chloro-4-(fluoro...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632978(US20230348453, Compound D1 | US12172993, Compound ...)
Affinity DataIC50: 12.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632981(US20230348453, Compound D9 | US12172993, Compound ...)
Affinity DataIC50: 12.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632981(US20230348453, Compound D9 | US12172993, Compound ...)
Affinity DataIC50: 12.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632953(US20230348453, Compound C1 | US12172993, Compound ...)
Affinity DataIC50: 13nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 13.4nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632954(US20230348453, Compound C2 | US12172993, Compound ...)
Affinity DataIC50: 14.4nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632958(US20230348453, Compound C6 | US12172993, Compound ...)
Affinity DataIC50: 14.7nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632979(US20230348453, Compound D7 | US12172993, Compound ...)
Affinity DataIC50: 17.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 17.7nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632956(US20230348453, Compound C4 | US12172993, Compound ...)
Affinity DataIC50: 17.7nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632969(US20230348453, Compound E4 | N-(2-chloro-4- (diflu...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632977(US20230348453, Compound E16 | N-(2-chloro-4- (difl...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632969(US20230348453, Compound E4 | N-(2-chloro-4- (diflu...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632975(US20230348453, Compound E13 | N-(2-chloro-4- (difl...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632976(US20230348453, Compound E15 | N-(4-chloro-2-fluoro...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632974(US20230348453, Compound E12 | N-(2-chloro-4-(fluor...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632971(US20230348453, Compound E9 | N-(2-chloro-4-(fluoro...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632972(US20230348453, Compound E10 | N-(2-chloro-4-(fluor...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632980(US20230348453, Compound D8 | US12172993, Compound ...)
Affinity DataIC50: 22.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632960(US20230348453, Compound C8 | US12172993, Compound ...)
Affinity DataIC50: 22.8nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandPNGBDBM632961(US20230348453, Compound C9 | US12172993, Compound ...)
Affinity DataIC50: 27.4nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: